Grace Therapeutics, Inc. (GRCE)

Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrahage

Wednesday, November 20, 2024 | 2:00 PM ET

Click to Register & Attend

Transforming the Treatment for an Acute Brain Injury

Grace Therapeutics is poised to disrupt the long-established standard of care in aneurysmal subarachnoid hemorrhage (aSAH) — a rare, life-threatening disease caused by the rupture of an aneurysm deep inside the brain.

Learn More About GTx-104

Welcome to Grace Therapeutics!

We have returned to our original name to reflect the extensive scientific accomplishments achieved under our original brand. To learn more about our mission and the exciting progress we are making in aneurysmal subarachnoid hemorrhage (aSAH), sign up for our news alerts.

High Disease Burden

aSAH has high mortality and morbidity and afflicts a relatively younger population causing a huge disease burden.

~50K

Cases per year in the U.S.

~70%

Death and dependency

~80%

Of patients under 65 years old

~50%

Of patients unconscious or dysphagic

~$220,000

Average hospital cost per patient

Limits of the Current Standard of Care

Nimodipine, an insoluble dihydropyridine calcium channel blocker, is the only FDA approved pharmacotherapy known to improve outcomes in aSAH.

In the US, it is available as large capsules or liquid solution which is administered orally every four hours for up to 21 days. In critically ill patients, this presents significant problems:
- Heavy dosing burden due to high first pass metabolism
- Poor hypotension management and frequent dose interruption
- Nasogastric tube delivery in unconscious or dysphagic patients
- Food effects and contraindicated with CYP3A inhibitors
- High pharmacokinetic variability with oral route

GTx-104

Grace Therapeutics has developed a breakthrough formulation of nimodipine that enables an intravenous infusion in aSAH patients, potentially solving the clinical problems with oral administration.

The program is currently enrolling patients in the pivotal Phase 3 safety trial (STRIVE-ON).

Potential value for patients, physicians, and hospitals -
- Improve outcomes
- Effective patient management
- Reduced cost of care

Learn More About GTx-104

About Grace Therapeutics

Grace Therapeutics is a late-stage biopharma company developing drug candidates that target rare and orphan diseases. We're poised to disrupt the standard of care in multiple neurological diseases. Our lead clinical assets' have been granted Orphan Drug Designation by the FDA, and we have a strong multi-layered intellectual property portfolio spanning the world.

Learn More About Grace Therapeutics